Filing Flows › Insight Molecular Diagnostics (IMDX) › Stock forecast & fair value
Insight Molecular Diagnostics (IMDX) stock forecast and price target
Insight Molecular Diagnostics (IMDX) trades at $2.49. 4 analysts' median price target is $8.50 (+241%), from $4.00 to $12.00.
Insight Molecular Diagnostics' latest quarter
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IMDX stock?
The median of 4 analysts' 12-month targets is $8.50, +241% from $2.49; the range is $4.00 to $12.00. The average rating is none.
Does Insight Molecular Diagnostics usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is IMDX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.